Dose-ranging cognitive report from the 25-patient Dilept pilot
Comparison in people · 2017
- What was studied
- 25 patients, mean age 33.4 ± 10.0 years, with ICD-10 F21.3. Dose groups: 5 at 60 mg/day, 5 at 120 mg/day and 15 at 200 mg/day. Seventy healthy volunteers provided reference test scores.
- Main finding
- The report describes greater changes across WAIS measures at 200 mg/day. These 25 patients match the dose-finding cohort described in the 2020 paper.
Reported findings and study design
WAIS comparison within the phase II dose-finding pilot, with baseline healthy reference data.
Dose, route and schedule
Dilept at 60, 120 or 200 mg/day for 28 days. Nineteen patients received phenazepam 0.5–2 mg/day starting on day 15.
Protocol source ↗ · Original journal PDF and cross-check against the 2020 pilot cohort.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Cognitive measures across doses | The authors reported larger improvements in psychomotor speed, attention and memory at 200 mg/day than at 60 or 120 mg/day. | |
| Treatment groups | 5, 5 and 15 patients across the ascending doses. Seventy healthy reference participants. |
Source for these results ↗ · Reviewed 2026-11-15
Study limitations and source details
Study limitations
- The healthy participants provided cognitive reference scores. They did not serve as a randomized treatment control. Dose groups were small and unequal.
Related publications may describe some of the same participants or experiments.
Source details
Original journal PDF and cross-check against the 2020 pilot cohort.
Sources checked
Citation
T. V. Kovalenok, A. A. Shabanova, I. O. Bogdanova, T. S. Syunyakov, N. Y. Ivashkina, N. G. Bogdan, G. G. Neznamov. Dose-ranging cognitive report from the 25-patient Dilept pilot Experimental and Clinical Pharmacology. 2017;80(8):8–14.
Study source ↗ · DOI 10.30906/0869-2092-2017-80-8-8-14 · Bibliography entry · Link to this summary